Reportlinker.com

Reportlinker.com

August 12, 2008 11:02 ET

AstraZeneca plc: Company Profile

LONDON, UNITED KINGDOM--(Marketwire - Aug. 12, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

AstraZeneca plc: PharmaVitae Profile

http://www.reportlinker.com/p091758/AstraZeneca-plc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

-Benchmark AstraZeneca's performance against key rivals in the ethical pharmaceutical sector

-Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune

-Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2013


CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Appendix 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 7
AstraZeneca: PharmaVitae forecasts at a glance 9
Strategic insight 10
SWOT analysis 20
Strengths 20
Weaknesses 22
Opportunities 23
Threats 24
CHAPTER 3 QUARTERLY NEWS UPDATE 30
Key findings 30
Product developments 31
Deals and alliances 32
Product deals 32
Technology deals 33
M&A activity 34
Company announcements 35
Future product milestones 37
CHAPTER 4 COMPANY STRUCTURE 39
Key findings 39
Company overview 40
Company history 40
M&A history 41
Astra AB and Zeneca Group plc 41
Subsequent M&A activity 43
Abgenix 43
Cambridge Antibody Technology (CAT) 43
KuDOS Pharmaceuticals 44
Arrow Therapeutics 44
MedImmune 45
Albireo 45
M&A strategy 45
CHAPTER 5 COMPANY SALES 49
Key findings 49
Prescription pharmaceutical sales and growth rate analysis, 2001-13 51
Product analysis 53
Product analysis, 2001-07 53
Product analysis, 2007-13 56
Therapy area analysis 61
Therapy area analysis, 2001-07 62
Therapy area analysis, 2007-13 65
Therapy area focus, 2001-13 69
Geographic analysis 71
Geographic analysis, 2001-07 72
Geographic analysis, 2007-13 73
Geographic focus, 2001-13 75
Launch/core/expiry analysis 76
Explanation of launch/core/expiry analysis 76
Launch analysis, 2007-13 77
Core analysis, 2007-13 79
Expiry analysis, 2007-13 80
Launch/core/expiry configuration, 2007-13 82
Molecule type analysis 84
Molecule type analysis, 2001-07 85
Molecule type analysis, 2007-13 86
Externalization analysis 90
Externalization analysis, 2001-07 91
Externalization analysis, 2007-13 93
CHAPTER 6 COMPANY FINANCIALS 97
Key findings 97
Reconciliation between PharmaVitae-formatted prescription pharma sales
and company-reported total sales, 2001-07 98
Financial statements, 2001-07 100
Profit and loss account, 2001-07 100
Balance sheet, 2001-07 104
Operating costs and profit analysis 107
Operating costs and profit analysis 2001-07 108
Operating cost ratio and profit margin analysis, 2001-07 109
Operating cost ratio and profit margin analysis, 2007-13 111
Operating costs and profit analysis, 2007-13 114
Return on capital employed analysis 117
Capital employed analysis, 2001-07 118
Return on capital employed (RoCE) analysis, 2001-07 120
Market capitalization analysis 123
Market capitalization analysis 2001-07 123
Total shareholder returns (TSR) analysis, 2001-07 126
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 128
Key findings 128
Overview 129
Crestor 130
Crucial differentiation in statin market 131
Potential market share gain via CRP indication 131
Statin market competitor dynamics 132
Positive impact of Zetia/Vytorin setback 133
Combination product with Abbott 133
Betaloc 134
XL formulation finally succumbs to generic competition 135
Nexium 137
PPI franchise lifecycle management 138
PPI market competitor dynamics 139
Generic threat in US market 139
Prilosec/Losec 141
Breakthrough product in GE market 142
Generic competition since 2002 142
Life cycle management 143
Arimidex 144
Following in the footsteps of Tamoxifen 145
ASCO recommendations 145
Aromatase inhibitor market competitor dynamics 146
Recentin 147
What is Recentin? 148
Bullish clinical trial design - taking on Avastin 148
Termination of NSCLC trial 149
Seroquel 151
Robust standing versus rival brands 152
Life cycle management strategy 153
Generic threat in US market 153
Symbicort 154
US market launch 155
Competitor dynamics 156
Lifecycle management strategy & SMART 156
Synagis 159
Monopoly position in RSV market 160
Numax 161
Considerable benefit over Synagis 162
Robust Phase III clinical data 163
CHAPTER 8 APPENDIX 164
R&D pipeline 164
References 165
Abbreviations 166
List of Tables 
Table 1: AstraZeneca - PharmaVitae forecasts at a glance 9
Table 2: AstraZeneca key product developments, Q1 2008 31
Table 3: AstraZeneca product deals and alliances, Q1 2008 32
Table 4: AstraZeneca technology deals and alliances, Q1 2008 33
Table 5: AstraZeneca M&A activity, 2008 34
Table 6: AstraZeneca company announcements, Q1 2008 35
Table 7: AstraZeneca future product milestones, 2008-10 37
Table 8: AstraZeneca product portfolio overview ($m), 2001-07 53
Table 9: AstraZeneca product portfolio overview ($m), 2007-13 56
Table 10: AstraZeneca therapy portfolio overview ($m), 2001-07 62
Table 11: AstraZeneca therapy portfolio overview ($m), 2007-13 65
Table 12: AstraZeneca portfolio overview by geographic region ($m),
2001-07 72
Table 13: AstraZeneca portfolio overview by geographic region ($m),
2007-13 73
Table 14: AstraZeneca launch portfolio overview ($m), 2007-13 77
Table 15: AstraZeneca core portfolio overview ($m), 2007-13 79
Table 16: AstraZeneca expiry portfolio overview ($m), 2007-13 80
Table 17: AstraZeneca portfolio overview by molecule type ($m), 2001-07 85
Table 18: AstraZeneca product portfolio overview by molecule type ($m),
2007-13 86
Table 19: AstraZeneca product portfolio overview by source ($m), 2001-07 91
Table 20: AstraZeneca product portfolio overview by source ($m), 2007-13 93
Table 21: Total AstraZeneca sales by business unit ($m), 2001-07 98
Table 22: AstraZeneca profit and loss account ($m), 2001-07 100
Table 23: AstraZeneca balance sheet ($m), 2001-07 104
Table 24: AstraZeneca operating revenue/cost analysis ($m), 2001-07 108
Table 25: AstraZeneca operating cost ratio analysis (% of total revenues),
2001-07 109
Table 26: AstraZeneca operating cost ratio analysis (% of total revenues),
2007-13 111
Table 27: AstraZeneca operating revenue/cost analysis ($m), 2007-13 114
Table 28: HPV vaccine royalty payments to AstraZeneca, 2007-13 ($m) 115
Table 29: AstraZeneca capital employed ($m), 2001-07 118
Table 30: AstraZeneca EBIT return on capital employed ($m), 2001-07 120
Table 31: AstraZeneca EBIT pre-tax return/Capital employed driver analysis
($m), 2001-07 121
Table 32: AZN market capitalization ($ billion), 2001-07 123
Table 33: AZN total shareholder returns (annual %), 2001-07 126
Table 34: Key products overview 129
Table 35: Crestor: overview 130
Table 36: Crestor: sales forecast ($m), 2007-13 131
Table 37: Betaloc: overview 134
Table 38: Betaloc: sales forecast ($m), 2007-13 135
Table 39: Nexium: overview 137
Table 40: Nexium: sales forecast ($m), 2007-13 138
Table 41: Prilosec/Losec: overview 141
Table 42: Prilosec/Losec: sales forecast ($m), 2007-13 142
Table 43: Arimidex: overview 144
Table 44: Arimidex: sales forecast ($m), 2007-13 145
Table 45: Recentin: overview 147
Table 46: Recentin: sales forecast ($m), 2007-13 148
Table 47: Seroquel: overview 151
Table 48: Seroquel: sales forecast ($m), 2007-13 152
Table 49: Symbicort: overview 154
Table 50: Symbicort: sales forecast ($m), 2007-13 155
Table 51: Synagis: overview 159
Table 52: Synagis: sales forecast ($m), 2007-13 160
Table 53: Numax: overview 161
Table 54: Numax: sales forecast ($m), 2007-13 162
Table 55: AstraZeneca R&D pipeline (Phase I-Phase III) 164
List of Figures 
Figure 1: AstraZeneca prescription pharmaceutical performance, sales ($m)
and growth rate (%), 2001-13 6
Figure 2: AstraZeneca financial performance ($m), 2001-13 8
Figure 3: AstraZeneca's blockbuster portfolio sales growth ($m), 2001-13 11
Figure 4: AstraZeneca revenues by molecule type ($m), 2001-13 15
Figure 5: AstraZeneca/MedImmune revenues ($m), 2001-13 16
Figure 6: AstraZeneca SWOT analysis 20
Figure 7: M&A/divestment history AstraZeneca 41
Figure 8: AstraZeneca prescription pharmaceutical performance, sales ($m)
and growth rate (%), 2001-13 51
Figure 9: AstraZeneca key sales growth driver & resistors ($m), 2001-07 54
Figure 10: AstraZeneca key sales growth drivers & resistors ($m), 2007-13 57
Figure 11: AstraZeneca prescription pharmaceutical sales by therapy area
($m), 2001-13 61
Figure 12: AstraZeneca prescription pharma sales by therapy area 
(% of total), 2001-13 69
Figure 13: AstraZeneca prescription pharmaceutical sales by geographic
region ($m), 2001-13 71
Figure 14: AstraZeneca drivers and resistors by geographic region ($m),
2001-07 72
Figure 15: AstraZeneca drivers and resistors by geographic region
($m), 2007-13 74
Figure 16: AstraZeneca prescription pharmaceutical sales by geographic
region (% of total), 2001-13 75
Figure 17: AstraZeneca launch/core/expiry configuration ($m), 2007-13 82
Figure 18: AstraZeneca prescription pharmaceutical sales by molecule
type ($m), 2001-13 84
Figure 19: AstraZeneca growth drivers & resistors by molecule type ($m),
2007-13 87
Figure 20: AstraZeneca prescription pharmaceutical sales by source ($m),
2001-13 90
Figure 21: AstraZeneca growth drivers & resistors by source ($m), 2001-07 91
Figure 22: AstraZeneca growth drivers & resistors by source ($m), 2007-13 94
Figure 23: AstraZeneca operating revenue/cost analysis ($m), 2001-13 107
Figure 24: AstraZeneca operating cost ratio analysis (% of total revenues),
2001-13 113
Figure 25: AstraZeneca return on capital employed, EBIT margin and capital
turnover, 2001-07 117
Figure 26: Return on capital employed formula 121
Figure 27: AstraZeneca market capitalization ($m), 2001-07 124
Figure 28: AstraZeneca total shareholder returns ($m), 2001-07 127


To order this report:

AstraZeneca plc: PharmaVitae Profile

http://www.reportlinker.com/p091758/AstraZeneca-plc-PharmaVitae-Profile.html

More market research reports here!

Contact Information